Tanvex Biopharma(TW:6541)
NT$28.15+-0.95 (+1.08%)
TW:6541
Tanvex Biopharma financials statements
NT$28.15
At close:+-0.95 (+1.08%)
Want to see TW:6541 full AI Analyst Report?
Tanvex Biopharma (6541) Ratios
Tanvex Biopharma Ratios
TW:6541's free cash flow for Q2 2026 was NT$-282.94M. For the 2026 fiscal year, TW:6541's free cash flow was decreased by NT$-45.07M and operating cash flow was NT$-237.87M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.87 | 1.94 | 1.66 | 3.44 | 9.67 |
| Quick Ratio | 1.35 | 1.31 | 1.36 | 2.88 | 9.30 |
| Cash Ratio | 1.10 | 1.08 | 1.05 | 2.59 | 8.95 |
| Solvency Ratio | -0.50 | -0.59 | -0.93 | -0.67 | -0.68 |
| Operating Cash Flow Ratio | -1.26 | -3.30 | -3.94 | -4.40 | -5.58 |
| Short-Term Operating Cash Flow Coverage | -33.51 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | NT$ -769.97M | NT$ -1.17B | NT$ -1.34B | NT$ -984.62M | NT$ 483.19M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.20 | 0.60 | 0.63 | 0.54 | 0.37 |
| Debt-to-Equity Ratio | 0.28 | 1.85 | 2.11 | 1.32 | 0.63 |
| Debt-to-Capital Ratio | 0.22 | 0.65 | 0.68 | 0.57 | 0.39 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.40 | 3.06 | 3.37 | 2.46 | 1.69 |
| Debt Service Coverage Ratio | -13.19 | -19.48 | -30.58 | -23.85 | -27.12 |
| Interest Coverage Ratio | -29.39 | -25.43 | -36.61 | -28.99 | -32.39 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 6.64 | 10.96 | 13.75 | 15.63 | 16.14 |
| Net Debt to EBITDA | -0.68 | -1.22 | -0.77 | -0.81 | 0.37 |
| Profitability Margins | |||||
| Gross Profit Margin | -109.91% | 23.91% | 97.22% | -86.36% | 65.67% |
| EBIT Margin | -346.21% | -3829.12% | -3385.86% | -7080.82% | -27690.84% |
| EBITDA Margin | -254.74% | -2995.62% | -2856.91% | -5824.08% | -23185.07% |
| Operating Profit Margin | -346.21% | -3912.40% | -3420.80% | -7080.82% | -27690.84% |
| Pretax Profit Margin | -374.89% | -3982.94% | -3479.30% | -7325.06% | -28545.86% |
| Net Profit Margin | -374.13% | -3983.94% | -3480.00% | -7325.17% | -28546.26% |
| Continuous Operations Profit Margin | -374.13% | -3983.94% | -3480.00% | -7325.17% | -28546.26% |
| Net Income Per EBT | 99.80% | 100.03% | 100.02% | 100.00% | 100.00% |
| EBT Per EBIT | 108.29% | 101.80% | 101.71% | 103.45% | 103.09% |
| Return on Assets (ROA) | -18.84% | -50.51% | -77.34% | -47.99% | -32.74% |
| Return on Equity (ROE) | -26.35% | -154.66% | -260.27% | -117.94% | -55.22% |
| Return on Capital Employed (ROCE) | -19.38% | -56.84% | -87.54% | -50.90% | -33.53% |
| Return on Invested Capital (ROIC) | -18.79% | -53.27% | -81.96% | -48.94% | -32.87% |
| Return on Tangible Assets | -32.86% | -50.64% | -77.43% | -48.16% | -32.81% |
| Earnings Yield | -11.15% | -13.65% | -25.47% | -13.26% | -8.16% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.25 | 36.93 | 5.93 | 8.12 | 2.14 |
| Payables Turnover | 8.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 2.02 | 0.12 | 0.02 | 0.24 | 0.02 |
| Fixed Asset Turnover | 0.15 | 0.02 | 0.03 | 0.01 | 0.00 |
| Asset Turnover | 0.05 | 0.01 | 0.02 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 0.78 | 0.12 | 0.13 | 0.02 | 0.00 |
| Cash Conversion Cycle | 248.13 | 3023.23 | 23175.03 | 1538.44 | 17934.79 |
| Days of Sales Outstanding | 112.18 | 9.88 | 61.56 | 44.93 | 170.35 |
| Days of Inventory Outstanding | 180.61 | 3013.35 | 23113.46 | 1493.51 | 17764.45 |
| Days of Payables Outstanding | 44.66 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 292.79 | 3023.23 | 23175.03 | 1538.44 | 17934.79 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -4.11 | -7.41 | -11.02 | -11.01 | -12.40 |
| Free Cash Flow Per Share | -6.85 | -8.13 | -11.57 | -11.80 | -12.67 |
| Dividend Paid and CapEx Coverage Ratio | -1.50 | -10.39 | -20.10 | -13.88 | -45.71 |
| Capital Expenditure Coverage Ratio | -1.50 | -10.39 | -20.10 | -13.88 | -45.71 |
| Operating Cash Flow Coverage Ratio | -0.64 | -0.70 | -0.83 | -0.73 | -0.79 |
| Operating Cash Flow to Sales Ratio | -2.51 | -33.18 | -23.35 | -59.54 | -256.57 |
| Free Cash Flow Yield | -12.45% | -12.46% | -17.94% | -11.56% | -7.50% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -8.97 | -7.33 | -3.93 | -7.54 | -12.25 |
| Price-to-Sales (P/S) Ratio | 33.57 | 291.86 | 136.63 | 552.35 | 3498.11 |
| Price-to-Book (P/B) Ratio | 2.36 | 11.33 | 10.22 | 8.89 | 6.77 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -8.03 | -8.02 | -5.57 | -8.65 | -13.34 |
| Price-to-Operating Cash Flow Ratio | -13.39 | -8.80 | -5.85 | -9.28 | -13.63 |
| Price-to-Earnings Growth (PEG) Ratio | 0.29 | 0.16 | -0.19 | 4.16 | 0.31 |
| Enterprise Value Multiple | -13.86 | -10.97 | -5.55 | -10.29 | -14.72 |
| Enterprise Value | 14.16B | 11.39B | 9.74B | 13.43B | 18.45B |
| EV to EBITDA | -13.86 | -10.97 | -5.55 | -10.29 | -14.72 |
| EV to Sales | 35.31 | 328.52 | 158.63 | 599.35 | 3412.29 |
| EV to Free Cash Flow | -8.45 | -9.03 | -6.47 | -9.39 | -13.01 |
| EV to Operating Cash Flow | -14.08 | -9.90 | -6.79 | -10.07 | -13.30 |
| Tangible Book Value Per Share | 9.39 | 5.71 | 6.28 | 11.39 | 24.90 |
| Shareholders’ Equity Per Share | 23.27 | 5.75 | 6.31 | 11.49 | 24.99 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Revenue Per Share | 1.64 | 0.22 | 0.47 | 0.18 | 0.05 |
| Net Income Per Share | -6.13 | -8.90 | -16.42 | -13.55 | -13.80 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.08 | 1.04 | 1.03 | 1.03 | 1.03 |
| Research & Development to Revenue | 0.47 | 30.52 | 27.79 | 60.32 | 255.92 |
| SG&A to Revenue | 0.98 | 8.84 | 7.39 | 10.48 | 40.55 |
| Stock-Based Compensation to Revenue | 0.02 | -0.06 | 5.32 | 3.01 | 9.79 |
| Income Quality | 0.67 | 0.83 | 0.67 | 0.81 | 0.90 |
Currency in TWD
